TP53 disruptive mutation predicts platinum-based chemotherapy and PD-1/PD-L1 blockade response in urothelial carcinoma

被引：0
|
作者：
Kaifeng, J. [1 ]
Zewei, W. [1 ]
Zhaopei, L. [2 ]
Jiejie, X. [3 ]
机构：
[1] Fudan Univ, Dept Urol, Zhongshan Hosp, Shanghai, Peoples R China
[2] Fudan Univ, Dept Urol, Shanghai Canc Ctr, Shanghai, Peoples R China
[3] Fudan Univ, Dept Biochem & Mol Biol, Shanghai, Peoples R China
来源：
EUROPEAN UROLOGY | 2024年 / 85卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
A0757
引用
收藏
页码：S1737 / S1738
页数：2
相关论文
共 50 条
  • [21] PD-1 and PD-L1 blockade in gastrointestinal malignancies
    Lote, Hazel
    Cafferkey, Catherine
    Chau, Ian
    CANCER TREATMENT REVIEWS, 2015, 41 (10) : 893 - 903
  • [22] Blood-based biomarker analysis in high PD-L1 expressing NSCLC treated with PD-1/PD-L1 based therapy with or without the addition of platinum-based chemotherapy.
    Fidler, Mary J.
    Villaflor, Victoria Meucci
    Rao, Amol
    Halmos, Balazs
    Bertino, Erin Marie
    Osarogiagbon, Raymond U.
    Carbone, David Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [23] Molecular predictors of response to PD-1/PD-L1 inhibition in urothelial cancer
    Viktoria Stühler
    Jan Moritz Maas
    Jonas Bochem
    Inês Anselmo da Costa
    Tilman Todenhöfer
    Arnulf Stenzl
    Jens Bedke
    World Journal of Urology, 2019, 37 : 1773 - 1784
  • [24] Molecular predictors of response to PD-1/PD-L1 inhibition in urothelial cancer
    Stuehler, Viktoria
    Maas, Jan Moritz
    Bochem, Jonas
    da Costa, Ines Anselmo
    Todenhoefer, Tilman
    Stenzl, Arnulf
    Bedke, Jens
    WORLD JOURNAL OF UROLOGY, 2019, 37 (09) : 1773 - 1784
  • [25] Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
    Dong, Zhong-Yi
    Zhong, Wen-Zhao
    Zhang, Xu-Chao
    Su, Jian
    Xie, Zhi
    Liu, Si-Yang
    Tu, Hai-Yan
    Chen, Hua-Jun
    Sun, Yue-Li
    Zhou, Qing
    Yang, Jin-Ji
    Yang, Xue-Ning
    Lin, Jia-Xin
    Yan, Hong-Hong
    Zhai, Hao-Ran
    Yan, Li-Xu
    Liao, Ri-Qiang
    Wu, Si-Pei
    Wu, Yi-Long
    CLINICAL CANCER RESEARCH, 2017, 23 (12) : 3012 - 3024
  • [26] Relevance of host and tumor PD-L1 expression in PD-L1 and PD-1 blockade
    Lin, Heng
    Wei, Shuang
    Vatan, Linda
    Kryczek, Ilona
    Zou, Weiping
    JOURNAL OF IMMUNOLOGY, 2017, 198 (01):
  • [27] Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
    Dong, Zhong-Yi
    Zhong, Wen-Zhao
    Liu, Si Yang
    Xie, Zhi
    Wu, Si-Pei
    Wu, Yi Long
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S432 - S433
  • [28] TIGIT and PD-1 expression atlas predicts response to adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer
    Liu, Zhaopei
    Zeng, Han
    Jin, Kaifeng
    Yu, Yanze
    You, Runze
    Zhang, Hongyi
    Liu, Chunnan
    Su, Xiaohe
    Yan, Sen
    Chang, Yuan
    Liu, Li
    Xu, Le
    Xu, Jiejie
    Zhu, Yu
    Wang, Zewei
    BRITISH JOURNAL OF CANCER, 2022, 126 (09) : 1310 - 1317
  • [29] TIGIT and PD-1 expression atlas predicts response to adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer
    Zhaopei Liu
    Han Zeng
    Kaifeng Jin
    Yanze Yu
    Runze You
    Hongyi Zhang
    Chunnan Liu
    Xiaohe Su
    Sen Yan
    Yuan Chang
    Li Liu
    Le Xu
    Jiejie Xu
    Yu Zhu
    Zewei Wang
    British Journal of Cancer, 2022, 126 : 1310 - 1317
  • [30] Conventional chemotherapy combined with PD-1/PD-L1
    不详
    MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2023, 16 (SUPPL 3) : 60 - 63
12345